MEDSIR and Ataraxis AI Launch Collaboration to Evaluate Ataraxis Breast in RCT Data
Browse All Resources
The partnership will evaluate the Ataraxis Breast platform in several international randomized controlled trials. Together, we aim to generate robust clinical evidence on the role of artificial intelligence in predicting outcomes and treatment effects in early-stage and metastatic breast cancer. The analyses will especially focus on novel therapies investigated in MEDSIR's groundbreaking trials, including CDK4/6 inhibitors and antibody-drug conjugates (ADCs).
With $20.4m in Series A funding from AIX Ventures, Peter Thiel, and healthcare and AI pioneers, Ataraxis AI is positioned to rapidly bring its first offering, Ataraxis Breast, to market
Francisco J. Esteva, Chief of Division of Hematology and Medical Oncology at Lenox Hill Hospital, shared on LinkedIn: “The clinical validation results of Ataraxis Breast–the first AI-native prognostic/predictive test for breast cancer patients are impressive.”
NEW YORK – Ataraxis AI is developing artificial intelligence-driven digital pathology tests that it believes may provide faster, more accurate, and more cost-effective answers to clinical questions about cancer patients' outcomes and recurrences than traditional molecular tests on the market.
Startup Ataraxis, which emerged from stealth Thursday, has developed a model that can predict the risk severity of breast cancer up to 30% more accurately than current tests.